AF
AUTL

Avanza Fonder’s Autolus Therapeutics AUTL Stock Holding History

Avanza Fonder’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,522
Closed -$107K – 488
2025
Q4 		$107K Hold
53,522
– – ﹤0.01% 474
2025
Q3 		$87.2K Hold
53,522
– – ﹤0.01% 417
2025
Q2 		$122K Buy
53,522
+32,246
+152% +$53.3K ﹤0.01% 405
2025
Q1 		$33.4K Sell
21,276
-10,494
-33% -$21.3K ﹤0.01% 459
2024
Q4 		$74.7K Buy
+31,770
New +$107K ﹤0.01% 429

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Avanza Fonder's AUTL Position: Q1 2026 in Review

Avanza Fonder sold out of Autolus Therapeutics (AUTL) in Q1 2026, closing a stake of 53,522 shares — an estimated $107K sold.

Avanza Fonder first reported a position in AUTL in Q4 2024 and held it in 5 quarters. The position peaked at $122K in Q2 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • Avanza Fonder reported no remaining Autolus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Avanza Fonder sold 53,522 Autolus Therapeutics shares in Q1 2026, an estimated $107K.
  • Avanza Fonder first reported a position in Autolus Therapeutics in Q4 2024 and held it in 5 quarters.
  • Avanza Fonder's Autolus Therapeutics position peaked at $122K in Q2 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.